Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Dexamethasone + Isatuximab + SAR439459 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Dexamethasone | Adexone | Desametasone | ||
Isatuximab | Sarclisa | SAR650984|isatuximab-irfc | CD38 Antibody 21 | Sarclisa (isatuximab-irfc) is a humanized monoclonal antibody against CD38 that induces anti-tumor immune reaction against CD38-positive tumor cells (PMID: 24987056). Sarclisa (isatuximab-irfc) in combination with Pomalyst (pomalidomide) and dexamethasone is FDA approved for use in patients with multiple myeloma who have received two or more prior therapies, in combination with Kyprolis (carfilzomib) and dexamethasone for patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy, and in combination with Velcade (bortezomib), Revlimid (lenalidomide), and dexamethasone for patients with newly diagnosed multiple myeloma ineligible for transplant (FDA.gov). |
SAR439459 | SAR-439459|SAR 439459 | TGFB (Pan) Antibody 5 | SAR439459 is a monoclonal antibody that targets transforming growth factor beta 1 (TGFB1, TGFbeta), which may lead to tumor regression in combination with PD-1 (PDCD1) immune checkpoint inhibitors (AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 2790). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04643002 | Phase Ib/II | Dexamethasone + Isatuximab + Pomalidomide Dexamethasone + Isatuximab + SAR439459 | Isatuximab in Combination With Novel Agents in RRMM | Recruiting | USA | NOR | ITA | ISR | GRC | FRA | DEU | AUS | 3 |